WPs » WP6 » Deliverables WP6

Deliverables WP6

6.1

Transcriptomics data from population-based discovery cohort (whole blood and lympoblastoid cellines)

18

6.2

Transcriptomics data from replication cohort (whole blood and lymphobalstoid cellines)

30

6.3

Transcriptomics data from cellular models of genetic variants of ALS

30

6.4

Putative biomarkers for ALS risk derived from transcriptomics analysis of target tissue 1: (MN from the CNS of ALS patients)

30

6.5

Validated biomarkers of fast and slow disease progression (from lymphoblastoid cell lines and whole blood)

48

6.6

Putative biomarkers for ALS risk derived from transcriptomics analysis of target tissue 3: (MN from the CNS of murine models of TDP-43 and FUS mutations and Unc13a knock-out)

30

6.7

Putative biomarkers for ALS risk derived from transcriptomics analysis of target tissue 2: (muscle biopsy tissue from ALS and control patients)

48

6.8

Putative biomarkers for ALS risk derived from transcriptomics analysis of target tissue 4: (MN derived from iPS cells generated from patient fibroblasts)

48